Detalles de la búsqueda
1.
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Am J Kidney Dis
; 67(6): 912-24, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26846333
2.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
J Clin Pharmacol
; 60(11): 1432-1440, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32603526
Resultados
1 -
2
de 2
1
Próxima >
>>